Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA wild-type |
Therapy | A-1210477 + WEHI-539 |
Indication/Tumor Type | breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA wild-type | breast cancer | predicted - sensitive | A-1210477 + WEHI-539 | Preclinical - Cell culture | Actionable | In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663). | 27974663 |
PubMed Id | Reference Title | Details |
---|---|---|
(27974663) | PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. | Full reference... |